ScholarLens Back to search
2017•Clinical and Experimental Health SciencesRequires access

Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml

Eren Altun, Gülay Turan, Figen Aslan, Serpil Paksoy

Open publisher page 0 citations

Abstract

Objectives: Prostate specific antigen (PSA) is the most commonly used markerfor prostate cancer. PSA-based screening has reduced disease-specific mortality.However, PSA is not specific for prostate cancer, but is specific for prostate tissue andincreases in benign conditions.Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or lesswere evaluated retrospectively with 636 patients who underwent prostate samplingbecause of the suspicion of prostate cancer.Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below1.5 ng / ml of PSA. Our results suggest that a significant number of cancers weredetected below 1.5 ng / ml of PSA.Conclusion: A significant number of prostate cancers are found below 1.5 ng / mlPSA. The lack of a PSA value that we can say without prostate cancer leads to theneed for a low cost and reliable marker.

About this research paper

What this paper is about

Objectives: Prostate specific antigen (PSA) is the most commonly used markerfor prostate cancer. PSA-based screening has reduced disease-specific mortality.However, PSA is not specific for prostate cancer, but is specific for prostate tissue andincreases in benign conditions.Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or lesswere evaluated retrospectively with 636 patients who underwent prostate samplingbecause of the suspicion of prostate cancer.Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below1.5 ng / ml of PSA. Our results suggest that a significant number of cancers weredetected below 1.5 ng / ml of PSA.Conclusion: A significant number of prostate cancers are found below 1.5 ng / mlPSA. The lack of a PSA value that we can say without prostate cancer leads to theneed for a low cost and reliable marker.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objectives: Prostate specific antigen (PSA) is the most commonly used markerfor prostate cancer. PSA-based screening has reduced disease-specific mortality.However, PSA is not specific for prostate cancer, but is specific for prostate tissue andincreases in benign conditions.Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or lesswere evaluated retrospectively with 636 patients who underwent prostate samplingbecause of the suspicion of prostate cancer.Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below1.5 ng / ml of PSA. Our results suggest that a significant number of cancers weredetected below 1.5 ng / ml of PSA.Conclusion: A significant number of prostate cancers are found below 1.5 ng / mlPSA. The lack of a PSA value that we can say without prostate cancer leads to theneed for a low cost and reliable marker.

Key concepts: Medicine, Prostate-specific antigen, Prostate, Antigen, Urology, Obstetrics, Internal medicine, Cancer

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml — Research Paper | ScholarLens